137P Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)

Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis

“…[22,23,26–29] In the pooled analysis, Leal study and Fedyanin study were included separately for different time points of ctDNA testing. [23,29] The heterogeneity of ctDNA in predicting postoperative RFS in gastric cancer was large, so we used a random effects model to calculate the pooled HR in Figure 4 (HR = 6.37, 95% CI: 2.70–15.01, P < .05; I 2 = 67%, P < .05). The high heterogeneity may be due to the different methods used to detect ctDNA and the different demographics of the included studies.…”

“…A total of 8 studies were included in the pooled analysis of postoperative ctDNA to predict the risk of tumor recurrence after surgery. [22][23][24][25][26][27][28][29] To fully explore the postoperative ctDNA prediction of postoperative tumor recurrence, we used a random-effects model and a fixed-effects model to calculate the combined RR as shown in Figure 3 and Supplementary Appendix 8, http:// links.lww.com/MD/K800, respectively. Postoperative ctD-NA-positive patients had a higher risk of tumor recurrence, with a pooled RR of 3.17, 95% CI:2.36-4.25 and 3.68, 95% CI:2.66-5.09) for both the random-effects and fixed-effects models, respectively.…”

“…A total of 6 studies were included in the pooled analysis of ctDNA for predicting postoperative RFS in gastric cancer. [22,23,[26][27][28][29] In the pooled analysis, Leal study and Fedyanin study were included separately for different time points of ctDNA testing. [23,29] The heterogeneity of ctDNA in predicting postoperative RFS in gastric cancer was large, so we used a random effects model to calculate the pooled HR in Figure 4 (HR = 6.37, 95% CI: 2.70-15.01, P < .05; I 2 = 67%, P < .05).…”

“…[17][18][19][20][21] Although several studies have explored ctDNA as a predictor of recurrence of gastric cancer after surgery in recent years, the current studies suffer from small sample sizes and inconsistent or even opposite results. [22][23][24][25][26][27][28][29] We will use meta-analysis to explore ctDNA ability to predict recurrence of gastric cancer after surgery and provide new evidence for the clinical application of ctDNA in gastric cancer. The primary aim of the study was to assess ctDNA to predict the recurrence of operable gastric cancer.…”

The Role of ctDNA in Gastric Cancer

“…Post-operative ctDNA offers prognostic information regarding recurrence and survival. A tumour-informed ddPCR assay was used in 42 patients with resected stage I–III GC and was found to have a sensitivity for detecting tumour-derived mutations of >70% [ 56 ]. A total of 50% of patients who had detectable ctDNA relapsed, with a 1-year DFS of 25.4%.…”